Confronto

Cerebrolysin vs. Sincalide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

96889-70-6

25126-32-3

Peso molecolare

nessun dato

1143.29 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

Meccanismo d'azione

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Sincalide

Sincalide activates CCK receptors, triggering gallbladder contraction and pancreatic enzyme secretion. This effect is used diagnostically to measure the gallbladder ejection fraction (e.g. in HIDA scintigraphy).

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Cerebrolysin	Sincalide
Austria	Su prescrizione	—
CN	Su prescrizione	—
Germania	Non chiaro	Non chiaro
RU	Su prescrizione	—
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Cerebrolysin and Sincalide?: Cerebrolysin is classified as "Ricerca (altro)", while Sincalide is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Sincalide: Sincalide is the synthetic C-terminal octapeptide of the hormone cholecystokinin (CCK-8). As Kinevac it is FDA-approved to stimulate gallbladder contraction for diagnostic imaging. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cerebrolysin or Sincalide?: The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Sincalide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cerebrolysin and Sincalide in Germany and the United States?: Germania: Cerebrolysin — Non chiaro, Sincalide — Non chiaro. Stati Uniti: Cerebrolysin — Non approvato, Sincalide — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Cerebrolysin

Sincalide

Austria

Su prescrizione

—

Su prescrizione

—

Germania

Non chiaro

Su prescrizione

—

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Cerebrolysin and Sincalide?

Cerebrolysin is classified as "Ricerca (altro)", while Sincalide is classified as "Ricerca (altro)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Sincalide: Sincalide is the synthetic C-terminal octapeptide of the hormone cholecystokinin (CCK-8). As Kinevac it is FDA-approved to stimulate gallbladder contraction for diagnostic imaging. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cerebrolysin or Sincalide?

The highest available evidence level is "RCT sull'uomo" for Cerebrolysin and "Studio sull'uomo" for Sincalide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cerebrolysin and Sincalide in Germany and the United States?

Germania: Cerebrolysin — Non chiaro, Sincalide — Non chiaro. Stati Uniti: Cerebrolysin — Non approvato, Sincalide — Su prescrizione. These are factual summaries with source and review date on the individual pages.